Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission: 3-Year Follow-Up of the Randomized Controlled LADI Trial

Lisa M A van Lierop; Monique J C Devillers; C Janneke van der Woude; Frank Hoentjen; Annemarie C de Vries; Ladi LTFU Study Group; Zlatan Mujagic

doi:10.1053/j.gastro.2025.09.023

Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission: 3-Year Follow-Up of the Randomized Controlled LADI Trial

Lisa M A van Lierop^*
, Monique J C Devillers
, C Janneke van der Woude
, Frank Hoentjen
, Annemarie C de Vries
, Ladi LTFU Study Group
, Zlatan Mujagic

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	404-407
Number of pages	4
Journal	Gastroenterology
Volume	170
Issue number	2
Early online date	19 Sept 2025
DOIs	https://doi.org/10.1053/j.gastro.2025.09.023
Publication status	Published - Feb 2026

Access to Document

10.1053/j.gastro.2025.09.023Licence: CC BY-NC-ND

Cite this

van Lierop, L. M. A., Devillers, M. J. C., van der Woude, C. J., Hoentjen, F., de Vries, A. C., Ladi LTFU Study Group, & Mujagic, Z. (2026). Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission: 3-Year Follow-Up of the Randomized Controlled LADI Trial. Gastroenterology, 170(2), 404-407. https://doi.org/10.1053/j.gastro.2025.09.023

@article{353dd969208e4d3a9ba7ac070e22f125,

title = "Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission: 3-Year Follow-Up of the Randomized Controlled LADI Trial",

author = "\{van Lierop\}, \{Lisa M A\} and Devillers, \{Monique J C\} and \{van der Woude\}, \{C Janneke\} and Frank Hoentjen and \{de Vries\}, \{Annemarie C\} and \{Ladi LTFU Study Group\} and Zlatan Mujagic",

year = "2026",

month = feb,

doi = "10.1053/j.gastro.2025.09.023",

language = "English",

volume = "170",

pages = "404--407",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders",

number = "2",

}

van Lierop, LMA, Devillers, MJC, van der Woude, CJ, Hoentjen, F, de Vries, AC, Ladi LTFU Study Group & Mujagic, Z 2026, 'Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission: 3-Year Follow-Up of the Randomized Controlled LADI Trial', Gastroenterology, vol. 170, no. 2, pp. 404-407. https://doi.org/10.1053/j.gastro.2025.09.023

Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission: 3-Year Follow-Up of the Randomized Controlled LADI Trial. / van Lierop, Lisa M A; Devillers, Monique J C; van der Woude, C Janneke et al.
In: Gastroenterology, Vol. 170, No. 2, 02.2026, p. 404-407.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission

T2 - 3-Year Follow-Up of the Randomized Controlled LADI Trial

AU - van Lierop, Lisa M A

AU - Devillers, Monique J C

AU - van der Woude, C Janneke

AU - Hoentjen, Frank

AU - de Vries, Annemarie C

AU - Ladi LTFU Study Group

AU - Mujagic, Zlatan

PY - 2026/2

Y1 - 2026/2

U2 - 10.1053/j.gastro.2025.09.023

DO - 10.1053/j.gastro.2025.09.023

M3 - Article

SN - 0016-5085

VL - 170

SP - 404

EP - 407

JO - Gastroenterology

JF - Gastroenterology

IS - 2

ER -

van Lierop LMA, Devillers MJC, van der Woude CJ, Hoentjen F, de Vries AC, Ladi LTFU Study Group et al. Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission: 3-Year Follow-Up of the Randomized Controlled LADI Trial. Gastroenterology. 2026 Feb;170(2):404-407. Epub 2025 Sept 19. doi: 10.1053/j.gastro.2025.09.023